Atritech
TriMed Staff | October 07, 2008 | Cardiovascular Business | Patient Care
Atritech (Booth 1424) is featuring its Watchman Left Atrial Appendage (LAA) closure technology, for which the FDA recently accepted its pre-market approval application based on the data of the PROTECT AF trial.  

The Watchman LAA system is designed to keep harmful sized blood clots that form in the left atrial appendage from entering your blood stream, potentially causing stroke or other complications. It is designed to be permanently placed just behind or at the opening of the left atrial appendage.

TriMed Staff

Related Content

Cardiologist moves to Mississippi to fight back against PAD and limit amputations
On-pump vs. off-pump CABG: No difference in long-term mortality, meta-analysis confirms
Peripheral artery disease is out of control in many rural, low income communities
The many benefits of using low-cost CT coronary calcium scoring to screen patients
Early feasibility study for implantable heart failure monitor moves forward 
Using 'magic' to calm pediatric patients during imaging exams

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Radiology Business
Philips launches new AI-enabled CT scanner aimed at cardiology at ECR 2024

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Design by Adaptive Theme
Trimed Popup
Trimed Popup